JP2017526674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526674A5 JP2017526674A5 JP2017510870A JP2017510870A JP2017526674A5 JP 2017526674 A5 JP2017526674 A5 JP 2017526674A5 JP 2017510870 A JP2017510870 A JP 2017510870A JP 2017510870 A JP2017510870 A JP 2017510870A JP 2017526674 A5 JP2017526674 A5 JP 2017526674A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- -1 bromo, iodo Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 0 *c1c(*)nc(*=C)nc1* Chemical compound *c1c(*)nc(*=C)nc1* 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019218684A JP6968141B2 (ja) | 2014-08-25 | 2019-12-03 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
| JP2021174486A JP2022017384A (ja) | 2014-08-25 | 2021-10-26 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041559P | 2014-08-25 | 2014-08-25 | |
| US62/041,559 | 2014-08-25 | ||
| US201562184212P | 2015-06-24 | 2015-06-24 | |
| US62/184,212 | 2015-06-24 | ||
| PCT/US2015/046777 WO2016033100A1 (en) | 2014-08-25 | 2015-08-25 | Novel ulk1 inhibitors and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218684A Division JP6968141B2 (ja) | 2014-08-25 | 2019-12-03 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526674A JP2017526674A (ja) | 2017-09-14 |
| JP2017526674A5 true JP2017526674A5 (enExample) | 2018-10-18 |
| JP6684780B2 JP6684780B2 (ja) | 2020-04-22 |
Family
ID=55400460
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510870A Active JP6684780B2 (ja) | 2014-08-25 | 2015-08-25 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
| JP2019218684A Active JP6968141B2 (ja) | 2014-08-25 | 2019-12-03 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
| JP2021174486A Pending JP2022017384A (ja) | 2014-08-25 | 2021-10-26 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218684A Active JP6968141B2 (ja) | 2014-08-25 | 2019-12-03 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
| JP2021174486A Pending JP2022017384A (ja) | 2014-08-25 | 2021-10-26 | 新規ｕｌｋ１阻害剤およびそれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10266549B2 (enExample) |
| EP (2) | EP3185868B1 (enExample) |
| JP (3) | JP6684780B2 (enExample) |
| CA (1) | CA2959347C (enExample) |
| DK (1) | DK3185868T3 (enExample) |
| ES (1) | ES2914099T3 (enExample) |
| WO (1) | WO2016033100A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3185868B1 (en) | 2014-08-25 | 2022-04-06 | Salk Institute for Biological Studies | Novel ulk1 inhibitors and methods using same |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) * | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| JOP20180113B1 (ar) | 2016-06-16 | 2022-03-14 | Denali Therapeutics Inc | مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية |
| EP3630291B9 (en) * | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| CN111278816B (zh) * | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| US10883992B2 (en) * | 2018-02-22 | 2021-01-05 | Regents Of The University Of Minnesota | Universal kinase substrates and methods of use thereof |
| CN112334475B (zh) | 2018-04-13 | 2024-10-29 | 癌症研究技术有限公司 | Bcl6抑制剂 |
| CN111362922A (zh) * | 2018-12-26 | 2020-07-03 | 上海喆邺生物科技有限公司 | 2,4-二氨基嘧啶衍生物及其用途 |
| CN111362928A (zh) * | 2018-12-26 | 2020-07-03 | 上海喆邺生物科技有限公司 | 2,4-二氨基嘧啶衍生物 |
| PL3966207T3 (pl) | 2019-05-10 | 2024-03-04 | Deciphera Pharmaceuticals, Llc | Fenyloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| PE20221083A1 (es) * | 2019-06-17 | 2022-07-05 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso |
| US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| AU2020385527B2 (en) * | 2019-11-21 | 2023-04-13 | Tyk Medicines, Inc. | Compound used as EGFR kinase inhibitor and use thereof |
| US20230227439A1 (en) * | 2019-12-06 | 2023-07-20 | Yale University | Spak/osr inhibitors and methods of using same |
| WO2021155185A1 (en) * | 2020-01-30 | 2021-08-05 | Sumitomo Dainippon Pharma Oncology, Inc. | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors |
| CN115023421B (zh) * | 2020-02-12 | 2024-05-24 | 优迈特株式会社 | 含氟嘧啶化合物及其制造方法 |
| AU2021218740A1 (en) * | 2020-02-14 | 2022-09-22 | Salk Institute For Biological Studies | Mono and combination therapies with ULK1/2 inhibitors |
| CA3171187A1 (en) * | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Inhibitors of ulk1/2 and methods of using same |
| US20230099804A1 (en) * | 2020-02-14 | 2023-03-30 | Salk Institute For Biological Studies | Macrocyclic ulk1/2 inhibitors |
| CN115443269A (zh) | 2020-03-31 | 2022-12-06 | 施万生物制药研发Ip有限责任公司 | 经取代的嘧啶和使用方法 |
| CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
| CN111732548B (zh) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途 |
| CN116249690A (zh) * | 2020-09-22 | 2023-06-09 | 百济神州有限公司 | 作为egfr抑制剂的吲哚啉化合物和衍生物 |
| CN116456985A (zh) * | 2020-09-23 | 2023-07-18 | 深圳市原力生命科学有限公司 | 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法 |
| CA3197050A1 (en) * | 2020-09-30 | 2022-04-07 | Salk Institute For Biological Studies | Patient selection biomarkers for treatment with ulk inhibitors |
| CN112920124B (zh) * | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| US20250042895A1 (en) * | 2021-10-06 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ulk1 and methods of use |
| CN117736198A (zh) * | 2022-09-21 | 2024-03-22 | 科辉智药生物科技(深圳)有限公司 | 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用 |
| US20240174647A1 (en) * | 2022-09-30 | 2024-05-30 | Neuron23, Inc. | Kinase modulators and methods of use thereof |
| WO2024140401A1 (zh) * | 2022-12-30 | 2024-07-04 | 捷思英达控股有限公司 | 作为激酶抑制剂的杂环化合物以及包括其的组合物 |
| CN116768885A (zh) * | 2023-03-14 | 2023-09-19 | 浙江大学 | N2-取代双环-2-氨基嘧啶类衍生物、其制备方法及医药用途 |
| WO2024233766A1 (en) * | 2023-05-10 | 2024-11-14 | Erasca, Inc. | Macrocyclic ulk1/2 inhibitors and their use thereof |
| WO2024249610A2 (en) * | 2023-05-30 | 2024-12-05 | The Trustees Of The University Of Pennsylvania | Radiolabeled compounds of trimethoprim and uses thereof |
| WO2025045182A1 (zh) * | 2023-09-01 | 2025-03-06 | 深圳众格生物科技有限公司 | Ulk1抑制剂及其制备方法和用途 |
| WO2025045203A1 (zh) * | 2023-09-01 | 2025-03-06 | 葆元生物医药科技(杭州)有限公司 | 杂环化合物及其中间体和应用 |
| WO2025117886A1 (en) * | 2023-12-01 | 2025-06-05 | Casma Therapeutics, Inc. | Ulk complex modulators and uses thereof |
| WO2025166161A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
| WO2025166124A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
| WO2025166180A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| ATE433447T1 (de) * | 2003-02-20 | 2009-06-15 | Smithkline Beecham Corp | Pyrimiidinverbindungen |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005049021A1 (en) | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| DE102007010801A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
| EP2231620A1 (en) * | 2007-12-03 | 2010-09-29 | Boehringer Ingelheim International GmbH | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| WO2009083185A2 (en) | 2007-12-28 | 2009-07-09 | Fovea Pharmaceuticals Sa | Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders |
| CN102066340B (zh) | 2008-04-16 | 2014-05-14 | 波托拉医药品公司 | 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物 |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP2427174A4 (en) | 2009-05-04 | 2014-01-15 | Santen Pharmaceutical Co Ltd | HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE |
| WO2010146132A1 (en) * | 2009-06-18 | 2010-12-23 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
| WO2011084523A2 (en) | 2009-12-15 | 2011-07-14 | The Salk Institute For Biological Studies | Ulk1 compositions, inhibitors, screening and methods of use |
| US9249466B2 (en) * | 2010-01-08 | 2016-02-02 | Agency For Science, Technology And Research | Methods and compositions for treating cancer |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| DE102010034699A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US20130252950A1 (en) * | 2010-09-23 | 2013-09-26 | President And Fellows Of Harvard College | Targeting mtor substrates in treating proliferative diseases |
| WO2012045195A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| US8691777B2 (en) | 2011-01-27 | 2014-04-08 | Emory University | Combination therapy |
| CA2864394C (en) | 2011-03-02 | 2021-10-19 | Jack Roth | A method of predicting a response to a tusc2 therapy |
| CN103458970A (zh) * | 2011-03-07 | 2013-12-18 | 泰莱托恩基金会 | Tfeb磷酸化抑制剂及其应用 |
| US20140343128A1 (en) * | 2011-11-15 | 2014-11-20 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway |
| US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| US20150250808A1 (en) * | 2012-10-15 | 2015-09-10 | Vojo P. Deretic | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
| NZ708563A (en) * | 2012-11-01 | 2019-02-22 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014098932A1 (en) | 2012-12-17 | 2014-06-26 | The Brigham And Women's Hosptial, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| CN103059030B (zh) * | 2012-12-28 | 2015-04-29 | 北京师范大学 | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 |
| JP2016506930A (ja) | 2013-01-25 | 2016-03-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患を処置するための化合物および方法 |
| EP3185868B1 (en) | 2014-08-25 | 2022-04-06 | Salk Institute for Biological Studies | Novel ulk1 inhibitors and methods using same |
-
2015
- 2015-08-25 EP EP15836833.2A patent/EP3185868B1/en active Active
- 2015-08-25 DK DK15836833.2T patent/DK3185868T3/da active
- 2015-08-25 EP EP22159448.4A patent/EP4070795A1/en active Pending
- 2015-08-25 US US15/505,532 patent/US10266549B2/en active Active
- 2015-08-25 JP JP2017510870A patent/JP6684780B2/ja active Active
- 2015-08-25 ES ES15836833T patent/ES2914099T3/es active Active
- 2015-08-25 CA CA2959347A patent/CA2959347C/en active Active
- 2015-08-25 WO PCT/US2015/046777 patent/WO2016033100A1/en not_active Ceased
-
2019
- 2019-02-06 US US16/269,468 patent/US10689397B2/en active Active
- 2019-04-19 US US16/389,784 patent/US10774092B2/en active Active
- 2019-04-19 US US16/389,793 patent/US20190284207A1/en not_active Abandoned
- 2019-12-03 JP JP2019218684A patent/JP6968141B2/ja active Active
-
2021
- 2021-10-26 JP JP2021174486A patent/JP2022017384A/ja active Pending